be taken to avoid an overdose that can be reached at lower doses.⁴ Impaired consciousness, stupor, coma and seizures are all described as side effects of this drug, especially in the case of overdose or intoxication. In our case, the addition of oxycodone-acetaminophen may have caused an additive CNS depression,⁴ lowering the threshold for epileptic activity, in a patient at risk because of the underlying silent CNS pathology. Treatment for epilepsy reversed both the clinical opcular signs and the abnormal EEG recordings. Our case recommends exercising caution in the use of oxycodone in patients undergoing dialysis.⁴

The association of an opcular syndrome with an NCSE in an adult patient is highly unusual. In their report on three cases of opcular syndrome, Thomas *et al*² describe an adult patient with myoclonic status epilepticus. Surface EEG, however, showed no evidence of cortical epileptic activity. The aetiology of these cases was either vascular or tumoral. Sasaguri *et al*⁵ described a patient with epilepsy, with a corpus callosum defect, who developed FCMS at the age of 27 years. In this case, however, FCMS was due to chronic herpes simplex encephalitis.

FCMS has only rarely been described as a manifestation of epileptic activity, and has been explained as a para-ictal phenomenon, similar to the Landau-Kleffner syndrome by Shafir and Prensky.³

The present case should draw attention to the possibility that an opcular syndrome in an adult may be due to NCSE and that in instances of FCMS the possibility of reversible (treatable) electrical activity should be ruled out.

Acknowledgements

We thank Mrs F Hedri, R Liebeskind, H Pollack and R Biton for technical assistance.

B Steiner-Birmanns

Department of Neurology, Shaare Zedek Medical Center, Jerusalem, Israel

G Munter

Department of Internal Medicine A, Shaare Zedek Medical Center

Y Benasouli

Department of Neurology, Shaare Zedek Medical Center

B Perl

Department of Emergency Medicine, Shaare Zedek Medical Center

M Itzhaki

Department of Orthopedic Surgery, Shaare Zedek Medical Center

I Korn Lubetzki

Department of Neurology, Shaare Zedek Medical Center

Correspondence to: Dr B Steiner-Birmanns, Department of Neurology, Shaare Zedek Medical Center, PO Box 3235, Jerusalem 94342, Israel; bbirmanns@szmc.org.il

doi: 10.1136/jnnp.2005.085282

Informed consent was obtained for publication of the patient's details in this report.

Competing interests: None.

References

- 1 Weller M. Anterior opcular cortex lesions cause dissociated lower cranial nerve palsies and anarthria but no aphasia: Foix-Chavany-Marie

syndrome and "automatic voluntary dissociation" revisited. *J Neurol* 1993;240:199-208.

- 2 Thomas P, Borg M, Suisse G, *et al*. Opcular myoclonic-anarthric status epilepticus. *Epilepsia* 1995;36:281-9.
- 3 Shafir Y, Prensky AL. Acquired epileptiform opcular syndrome: a second case report, review of the literature, and comparison to the Landau-Kleffner syndrome. *Epilepsia* 1995;36:1050-7.
- 4 Anon. Drug database. In: Bradley WG, Daroff RB, Fenichel GM, Jankovic J, eds. *Neurology in clinical practice*. Electronic edition. Amsterdam: Elsevier, 2005. <http://www.nicp.com/> (accessed 1 Sep 2005).
- 5 Sasaguri H, Sodeyama N, Maejima Y, *et al*. Slowly progressive Foix-Chavany-Marie syndrome associated with chronic herpes simplex encephalitis. *J Neurol Neurosurg Psychiatry* 2002;73:203-4.

Successful immunosuppressive treatment and long-term follow-up of anti-Ri-associated paraneoplastic myelitis

Antineuronal antibody-associated paraneoplastic neurological syndromes (PaNSs) result from tumour-stimulated autoimmune attacks against components of the nervous system. The rare antineuronal antibody anti-Ri (ANNA-2) was initially thought to be closely associated with paraneoplastic opsoclonus-myoclonus syndrome. Recently, however, it has been found in several other PaNSs.¹ First-line treatment in PaNSs is removal of the underlying tumour. Second-line treatment is immunosuppression, which, although extensively used, especially when no tumour is detected, is often ineffective. Often, patients die from relentlessly progressive PaNS rather than the underlying neoplasm.² Here, we report the 2-year follow-up of an anti-Ri-positive steroid-responsive myeloneuropathy. No tumour was detected. Immunosuppressive treatment was tailored on the basis of clinical relapses, inflammatory changes in cerebrospinal fluid (CSF) and somatosensory evoked potentials (SEPs).

A 65-year-old woman, a retired administrator, was referred to our department with a 10-month history of progressive gait difficulties and ascending sensory loss in her legs, eventually having become wheelchair bound. Her medical history was unremarkable apart from enlarged axillary lymph nodes that were excised 9 months earlier. Histological examination showed only inflammatory changes. She had received hormone replacement therapy for 11 years. She never smoked.

On neurological examination, deep tendon reflexes were absent. She had spastic paraparesis with bilateral extensor plantar responses. Bilateral hypaesthesia for light touch up to the knees and diminished vibration sense were observed distally in her legs. Magnetic resonance imaging (MRI) showed symmetrical T2-hyperintense multi-segmental (C6-TH3/TH8-TH12) cervicothoracic lesions of the spinal cord, with gadolinium enhancement restricted to the lateral parts (fig 1A). Cerebral MRI showed only minor microangiopathic changes. Nerve conduction studies showed normal tibial nerve conduction velocities (NCV), slightly reduced right median NCV (forearm 41 m/s, normal >41 m/s) and moderately reduced sural NCV (32 m/s, normal >40 m/s). Right median (32 ms, normal 28 ms) and tibial (61 ms, normal 52 ms) nerve F-wave latencies were prolonged, in keeping with polyneuropathy. SEPs after median nerve stimulation were normal; tibial SEP was

absent bilaterally. An examination of the CSF showed pleocytosis (80% lymphocytes) and disturbed blood-CSF barrier (fig 1B). Microbiological serology of serum and CSF showed no evidence of acute infection. Routine laboratory tests were normal. Rheumatoid factor, anti-neutrophil and anti-nuclear autoantibodies were not found. Immunofluorescence screening for onconeural antibodies using monkey cerebellum, jejunum and peripheral nerve showed high-titre antineuronal nuclear antibodies in serum (1:1920) and CSF, with a pattern suggestive of anti-Ri antibodies. Subsequent immunoblots with recombinant targets of anti-Ri, anti-Hu, anti-Yo and amphiphysin antibodies (serum or CSF) confirmed anti-Ri specificity. In addition, no anti-Ma2, anti-CRMP5, anti-ANNA-3, anti-PCA2, anti-PCA-Tr, anti-N or anti-P/Q-calcium channel, anti-striated muscle or anti-acetylcholine receptor antibodies were found. Whole-body fluorodeoxyglucose-positron emission tomography (FDG-PET) was inconspicuous. Mammography showed bilateral mastopathy. Carcinoembryonic antigen, CA15-3, CA125, α -fetoprotein, human chorionic gonadotropin, and β 2-microglobulin were not raised.

The patient was treated with high-dose steroids for 14 days. In weeks, she regained the ability of walking with support. Sensory disturbances improved. Plantar responses became flexor. A first relapse (relapse 1, fig 1B) led to a recurring inability to walk unaided, reappearance of extensor plantar responses and sensory deficits for all qualities below TH12. Spinal MRI showed increased signal abnormalities and gadolinium enhancement. The number of white blood cells in the CSF increased and blood-CSF barrier dysfunction became pronounced. Although a high-dose steroid treatment and slow tapering led to improved muscle strength, reduced sensory disturbances and increased walking distance as well as normalisation of abnormalities of the CSF, in the ensuing year, two more relapses (fig 1B) were witnessed, each after tapering steroids below 20 mg prednisolone and associated with the reappearance of inflammatory CSF (fig 1B). Increased prednisolone was followed by clinical improvement and alleviated abnormalities of the CSF. Peroneal SEP latencies were established as an additional parameter. Every relapse led to increased residual deficits. Eventually, oligoclonal bands appeared and remained detectable, mild pleocytosis persisted and peroneal SEP continued to deteriorate. As steroidal side effects were no longer tolerable, monthly cyclophosphamide-pulsed treatment (650 mg/m² body surface) was started. During the following 9 months, the patient's condition stabilised and CSF findings normalised. Six-monthly FDG-PET did not disclose an underlying malignancy. Owing to side effects, cyclophosphamide was eventually discontinued. As azathioprine and mycophenolate mofetil led to lymphopenia, intravenous immunoglobulins were started recently. So far, there has been no relapse.

This patient with anti-Ri antibodies presented with myeloneuropathy. The non-classical clinical presentation in combination with a well-characterised onconeural antibody fulfils the criteria of a definite PaNS.³ That no tumour was detected during 36 months is compatible with anti-Ri PaNS. Only 3% of patients have not developed cancer within 3 years of follow-up.^{1,3} The history of enlarged lymph nodes, oestrogen treatment and mastopathy is suggestive of

Figure 1 (A) Coronal and sagittal sections of gadolinium-enhanced T1-weighted spinal magnetic resonance image showing symmetrical contrast enhancement of the lateral aspects of the spinal cord. Asterisk indicates TH12. Dashed line indicates the level of axial section. (B) Clinical course of the patient starting from May 2003. Continuous line with closed boxes: white blood cells (WBCs) (cells/ μ l), left y axis, normal $<5/\mu$ l) in the cerebrospinal fluid; dashed line with filled circles: $Q_{alb} \times 10^3$ (albumin ratio serum/cerebral spinal fluid as a parameter of blood brain-barrier function, left y axis, normal <8.4); dashed line with filled triangles: differences of left peroneal somatosensory evoked potential (SEP) latencies compared with those from November 2003 (ms, right y axis). Encircled numbers: numbered clinical relapses; open arrows: cyclophosphamide pulses; line of asterisks: steroid treatment, roughly corresponding in size of dose; filled line above asterisks: azathioprine treatment.

occult breast cancer; however, histological examination and PET scanning remained negative. Another autoimmune non-paraneoplastic aetiology of myelitis cannot be excluded completely. However, no other autoantibodies—for example, rheumatoid factor and Sjögren's syndrome antibodies—were detected. Immunofluorescence and recombinant immunoblot confirmed anti-Ri specificity; however, no immunoblot using cerebellar extracts was carried out. Therefore, antibodies targeting neuronal proteins other than those tested cannot be excluded.

Classically, anti-Ri antibodies occur in PaNS with brain stem dysfunction.^{1–5} Spinal involvement has been described in 12–16% of cases,^{1–5} but, to our knowledge, this is the first detailed clinical and MRI description of anti-Ri myelitis with distinct signal abnormalities not usually encountered in infectious or other autoimmune myelitis. Although polyneuropathy was previously reported in 20% of anti-Ri patients, in almost half of these cases, additional onconeural antibodies (anti-Hu, CRMP5/CV2) were also present.¹ As none of these were detected in this case, it is plausible that myeloneuropathy was directly related to anti-Ri antibodies.

The long-term treatment of patients with PaNS without detectable cancer is a challenging situation. It is often unclear whether clinical improvements can be attributed to treatment or simply reflect the natural clinical course. In the present case, the former seems more likely. Over 2 years, both starting and increasing the dosage of steroids was followed by clinical improvement and reduced CSF inflammatory changes. As a corollary, tapering of steroids had an opposite effect. Of note, steroid responsiveness was previously reported also in patients with other anti-Ri positive PANSS.^{1–5}

In summary, we report a patient with anti-Ri positive myeloneuropathy responding to immunosuppression. White blood cells in the CSF, CSF-blood-barrier function and peroneal SEPs proved to be useful in monitoring therapeutic responses. This case shows that long-term treatment of anti-Ri PaNS can be successful, but still remains a challenge.

Acknowledgements

We thank Prof Raymond Voltz, Cologne, Germany, and Dr Vanda Lennon, Rochester, USA, for advice

and confirmation of antibodies. A Münchau was supported by the Volkswagenstiftung (Grant I/78 553).

F Leypoldt

Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

P Eichhorn

Department of Clinical Chemistry, University Hospital Großhadern, Munich, Germany

C Saager

Department of Neuroradiology, Medical Center Hamburg-Eppendorf

A Münchau, J Lewerenz

Department of Neurology, University Medical Center Hamburg-Eppendorf

Correspondence to: J Lewerenz, Department of Neurology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20251 Hamburg, Germany; jleweren@uke.uni-hamburg.de

doi: 10.1136/jnnp.2005.086140

Competing interests: None.

References

- Pitcock SJ, Lucchinetti CF, Lennon VA. Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. *Ann Neurol* 2003;53:580–7.
- Graus F, Keime-Guibert F, Rene R, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. *Brain* 2001;124(Pt 6):1138–48.
- Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. *J Neurol Neurosurg Psychiatry* 2004;75:1135–40.
- Luque FA, Furneaux HM, Ferziger R, et al. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. *Ann Neurol* 1991;29:241–51.
- Shams'ili S, Grefkens J, de Leeuw B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. *Brain* 2003;126(Pt 6):1409–18.

Audit of resource use in patients with non-organic disorders admitted to a UK neurology unit

Patients with non-organic disorders are commonly seen in neurology outpatient

clinics¹ and use a considerable amount of health service resources.² Less is known, however, about the prevalence of these disorders among patients who occupy inpatient neurology beds in the UK.^{3–4}

We set out to establish the number of patients with non-organic neurological disorders admitted to the neurology ward in Oxford, UK, during a 12-month period and to estimate the hospital resources used by these patients.

Methods

The ward serves a population of about 2.4 million. A relatively small proportion of inpatients are admitted through their general practitioners (GPs). The unit provides a regional and supraregional videotelemetry service. We acknowledge that these factors may limit the generalisability of some of our results.

We studied 693 consecutive neurology ward admissions (563 patients) between August 2001 and August 2002. These admissions were split into two lists on the basis of apparent specificity of the diagnostic coding term (DCT) assigned by the hospital coding office: list 1 (n = 380), DCT organic and unambiguous (eg, Myasthenia gravis); and list 2 (n = 313), DCT non-specific (eg, epilepsy, unspecified). We predicted that any admissions with a non-organic diagnosis would be contained within list 2.

After reviewing the medical discharge summary (and subsequent correspondence if necessary), each admission from list 2 was classified (AMP/BM) as being either organic or possibly non-organic according to our study criteria. The study criteria can be seen online at <http://jnnp.bmjournals.com/supplemental>. CB and YH then independently examined all the possible non-organic cases (n = 58) and classified them as either definitely organic or definitely non-organic. Admissions were finally classified as non-organic only if both YH and CB agreed with this diagnosis. For nine cases, either or both of the examiners believed that a non-organic diagnosis was possible but not definite, and these admissions were therefore classified as uncertain. To determine the accuracy of the DCT, the discharge summaries from a random sample of 80 patients from list 1 were also examined.

For all non-organic admissions, the following variables were recorded: duration of ward